GlaxoSmithKline


TeenScreen: Who Pays for Treatment and Drugs?? Sun, 29 May 2005 In her latest examination of the President’s Commission on Mental Health recommendation for universal mental health screening, Evelyn Pringle focuses on the $$$ it costs and on how screening, followed by prescribing psychotropic drugs, is bankrupting of public health […]

TeenScreen: Who Pays for Treatment and Drugs??


UK Doctors told to stop giving antidepressants to children – Glaxo Warns of Paxil Birth Defects Wed, 28 Sep 2005 Related Link – See Guidelines at: http://www.nice.org.uk/page.aspx?o=273073 The UK National Health Service has takenĀ a decisive, responsible step to protect the lives of children who are being exposed to serious risks […]

UK Doctors told to stop giving antidepressants to children – ...


Fast growing business: Unethical clinical trials in India – Asia Times Tue, 27 Jul 2004 Asia Times reports: “India increasingly emerges as a preferred destination for outsourcing clinical trials – testing of new drugs on humans – the country may also be heading toward providing the greatest source of human […]

Fast growing business: Unethical clinical trials in India – Asia ...



Lilly duloxetine drug trial–19 Quit after a suicide – Philadelphia Inquirer Fri, 13 Feb 2004 19-year old Teri Johnson’s suicide occurred one week after an FDA advisory committee had urged the FDA to issue warnings about prescribing antidepressant drugs for children under 18 because of an increased risk in suicide. […]

Lilly duloxetine drug trial–19 Quit after a suicide – Philadelphia ...


Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs Thu, 18 Nov 2004 The Associated Press reports that at a Congressional hearing today, Dr. David Graham a drug safety expert at the FDA told the Senate Finance Committee that the public is “virtually defenseless” if another medication such as Vioxx […]

Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs


Conflicts of Interest policy – New York Times Sun, 28 Mar 2004 To: ‘Executive-editor@nytimes’; ‘gcollins@nytimes’; ‘arosenthal@nytimes’; ‘pboffey@nytimes’; ‘lchang@nytimes’; ‘oped@nytimes’ Cc: ‘Daniel Okrent’ ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure http://www.ahrp.org FYI Friday’s New York Times included the following Editor’s Note on the paper’s Op Ed page: […]

Conflicts of Interest policy – New York Times



“Drug Companies Should Make Their Studies Public” NYT Wed, 13 Aug 2003 Concealed and inaccessible research findings are undermining the integrity of medicine, the advancement of scientific knowledge, and most importantly, secrecy is putting people’s lives in jeopardy because prescribing doctors are ignorant about adverse – even lethal – drug […]

"Drug Companies Should Make Their Studies Public" NYT


Time to put drug giants on trial – Scotsman (UK) Fri, 20 Jun 2003 The UK media-including BBC, the Guardian, the Scotsman, the London Times, and others–have been informing the British public about the hidden health hazards underlying the industry-controlled drug approval and drug marketing process. Current practices have led […]

Time to put drug giants on trial – Scotsman (UK)




Jeffrey Drazen editor NEJM Turns Activist on Drug Trials Thu, 26 May 2005 Journal editors, one by one are trying to retrieve the integrity of their publications, at last recognizing that the pharamaceutical industry is a corrupting factor in medical research and the information disseminated about medicine. Jeffrey Drazen who […]

Jeffrey Drazen editor NEJM Turns Activist on Drug Trials